Global Blood Safety, Optimizing Treatment and the Affordability of Care Speakers: Brian O’Mahony, Mark W. Skinner Over the next few years, we will see a revolution in treatment not seen since the 1960s. Treatment products will advance on all fronts, from viral-inactivated (solvent detergent) cryoprecipitate, biosimilars of current therapies and treatment products with substantially enhanced efficacy to the increasing likelihood that through gene transfer a “cure” may become a reality. The blood safety concerns of the past have been replaced by current concerns about maintaining vigilance against such blood-borne agents as viruses and prions. Equally important are the challenges of adequate factor supply and access to products around the world. This session describes how patients have started to join forces to bring all key stakeholders together to ensure that the views of product users are considered when it comes to access to these vital therapies. During this session we also address the challenges of answering US government and payer demands for evidence-based medicine, and cost justification for the introduction of new therapies and enhancement of current treatments. | 
